| Literature DB >> 28859336 |
Andrew M Donson1, John Apps1, Andrea M Griesinger1, Vladimir Amani1, Davis A Witt1, Richard C E Anderson1, Toba N Niazi1, Gerald Grant1, Mark Souweidane1, James M Johnston1, Eric M Jackson1, Bette K Kleinschmidt-DeMasters1, Michael H Handler1, Aik-Choon Tan1, Lia Gore1, Alex Virasami1, Jose Mario Gonzalez-Meljem1, Thomas S Jacques1, Juan Pedro Martinez-Barbera1, Nicholas K Foreman1, Todd C Hankinson1.
Abstract
Pediatric adamantinomatous craniopharyngioma (ACP) is a highly solid and cystic tumor, often causing substantial damage to critical neuroendocrine structures such as the hypothalamus, pituitary gland, and optic apparatus. Paracrine signaling mechanisms driving tumor behavior have been hypothesized, with IL-6R overexpression identified as a potential therapeutic target. To identify potential novel therapies, we characterized inflammatory and immunomodulatory factors in ACP cyst fluid and solid tumor components. Cytometric bead analysis revealed a highly pro-inflammatory cytokine pattern in fluid from ACP compared to fluids from another cystic pediatric brain tumor, pilocytic astrocytoma. Cytokines and chemokines with particularly elevated concentrations in ACPs were IL-6, CXCL1 (GRO), CXCL8 (IL-8) and the immunosuppressive cytokine IL-10. These data were concordant with solid tumor compartment transcriptomic data from a larger cohort of ACPs, other pediatric brain tumors and normal brain. The majority of receptors for these cytokines and chemokines were also over-expressed in ACPs. In addition to IL-10, the established immunosuppressive factor IDO-1 was overexpressed by ACPs at the mRNA and protein levels. These data indicate that ACP cyst fluids and solid tumor components are characterized by an inflammatory cytokine and chemokine expression pattern. Further study regarding selective cytokine blockade may inform novel therapeutic interventions.Entities:
Keywords: Adamantinomatous craniopharyngioma; Craniopharyngioma cyst; Cytokine; IL-6; Immunomodulation; Inflammatory
Mesh:
Substances:
Year: 2017 PMID: 28859336 PMCID: PMC6005018 DOI: 10.1093/jnen/nlx061
Source DB: PubMed Journal: J Neuropathol Exp Neurol ISSN: 0022-3069 Impact factor: 3.685